Following the announcement that Nyxoah S.A. (NASDAQ: NYXH) will be attending many upcoming investor events, the company’s shares experienced a sharp rise. After-hours trading saw NYXH stock rise 6.68% to $7.99, more than offsetting a -2.73% loss it had sustained during regular session trading, which concluded at $7.49.
NYXH To Take Part in Important Investor Conferences
It has been revealed that Nyxoah (NYXH) will present at three significant investor conferences that will take place in New York City. The CEO of Nyxoah, Olivier Taelman, will provide an update on the business next Monday at the Baird Global Healthcare Conference.
Following that, the CEO of the firm will also take part to provide such updates to more investors on Tuesday at the HC Wainwright 26th Annual Global Investment Conference and on September 18, 2024 at the Cantor Global Healthcare Conference. In addition, Nyxoah will arrange one-on-one meetings with attending institutional investors.
Nyxoah Celebrated The Strategic Advancements and Milestones
In recognition of its significant achievements, Nyxoah was given the privilege to ring the Nasdaq Closing Bell on August 29, 2024. The introduction of the company’s Genio hypoglossal nerve stimulation technology to the US market was also a cause for celebration. Obstructive sleep apnea (OSA) is a major breathing problem that happens during sleep and is associated with cardiovascular illnesses and an increased risk of mortality.
Financial Position and Market Readiness
The U.S. healthcare market represents a crucial opportunity for Nyxoah, given its size and strategic importance. Nyxoah is well-positioned for a successful market debut because to solid clinical findings from the DREAM trial, significant finance, and a strengthened U.S. marketing team.
The FDA has received the last module of Nyxoah’s Premarket clearance (PMA) filing, and U.S. clearance is expected by the end of 2024. The Genio system may be made available in the United States as early as 2025, assuming clearance is given.
Nyxoah has also announced positive results from the DREAM study and is building its U.S. commercial team, led by Scott Holstine as Chief Commercial Officer. The company’s market entry is fully financed following the successful raising of over €85 million, which includes €48.5 million from an equity offering and a €37.5 million loan agreement with the European Investment Bank (EIB).